Singular Genomics Systems Inc OMIC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OMIC is a good fit for your portfolio.
News
-
Singular Genomics Reports Recent Highlights and First Quarter 2024 Financial Results
-
Singular Genomics to Report First Quarter 2024 Financial Results on May 14, 2024
-
Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results
-
Singular Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024
Trading Information
- Previous Close Price
- $0.43
- Day Range
- $0.40–0.45
- 52-Week Range
- $0.31–1.14
- Bid/Ask
- $0.38 / $0.44
- Market Cap
- $31.82 Mil
- Volume/Avg
- 192,950 / 113,598
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.70
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.06%
Company Profile
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Small Value
- Total Number of Employees
- 127
- Website
- https://www.singulargenomics.com
Comparables
Valuation
|
Metric
|
OMIC
|
VCYT
|
TIHE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 26.22 | — |
Price/Book Value | 0.18 | 1.54 | — |
Price/Sales | 10.70 | 4.39 | — |
Price/Cash Flow | — | 30.56 | — |
Price/Earnings
OMIC
VCYT
TIHE
Financial Strength
|
Metric
|
OMIC
|
VCYT
|
TIHE
|
|---|---|---|---|
Quick Ratio | 9.60 | 4.41 | — |
Current Ratio | 10.51 | 5.00 | — |
Interest Coverage | −93.37 | −11,324.57 | — |
Quick Ratio
OMIC
VCYT
TIHE
Profitability
|
Metric
|
OMIC
|
VCYT
|
TIHE
|
|---|---|---|---|
Return on Assets (Normalized) | −27.78% | 8.19% | — |
Return on Equity (Normalized) | −37.15% | 8.76% | — |
Return on Invested Capital (Normalized) | −31.40% | 7.87% | — |
Return on Assets
OMIC
VCYT
TIHE
Medical Instruments & Supplies Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ISRG
| Intuitive Surgical Inc | Prchtgdcn | Cqpw | $135.1 Bil | |
BDX
| Becton Dickinson & Co | Vrqlkzmch | Fjbdzj | $68.5 Bil | |
ALC
| Alcon Inc | Fzcwjtgz | Stnmq | $40.4 Bil | |
RMD
| ResMed Inc | Znpctqkdk | Zkjrg | $32.0 Bil | |
CLPBY
| Coloplast A/S ADR | Sdqswbrpq | Cfqb | $27.4 Bil | |
WST
| West Pharmaceutical Services Inc | Hpdrbmwz | Cgy | $26.2 Bil | |
COO
| The Cooper Companies Inc | Qdhrxmhcl | Krmhtg | $18.5 Bil | |
BAX
| Baxter International Inc | Fhshdxtgs | Ndbsqt | $18.1 Bil | |
HOLX
| Hologic Inc | Ndyzvbt | Lcdhtz | $17.6 Bil | |
ATR
| AptarGroup Inc | Lnvklvdm | Ypxpqg | $9.8 Bil |